NCT01933906View on ClinicalTrials.gov

Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 30, 2013

Primary Completion Date

November 14, 2018

Study Completion Date

November 14, 2018

Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
DRUG

P1101

Trial Locations (4)

4600

Klinikum Wels-Grieskirchen GmbH, IV. Interne Abteilung, Wels

5020

Universitätsklinikum der PMU Salzburg, Universitätsklinik für Innere Medizin III, Salzburg

A-6020

Universitätskliniken Innsbruck, Univ.-Klinik f.Innere Medizin V Hämtologie u. Onkologie, Innsbruck

A-4020

Ordensklinikum Linz - Elisabethinen, Linz

Sponsors
All Listed Sponsors
collaborator

AOP Orphan Pharmaceuticals AG

INDUSTRY

lead

Arbeitsgemeinschaft medikamentoese Tumortherapie

OTHER

NCT01933906 - Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response | Biotech Hunter | Biotech Hunter